Clinical Trials - Kurve Therapeutics

Kurve Therapeutics Clinical Trials

As we advance through each clinical trial phase, we want to offer transparency and insight into our efforts. We have successfully met our endpoints in Phase IIb in 3 separate clinical trials and are currently Phase III ready.

This is where you can find the latest list of clinical trials that Kurve has participated in, for which our next-generation technology was the device of choice.

Field of Study	Conducted by
Alzheimer’s Disease	Johns Hopkins
Alzheimer’s Disease (Phase I, II and IIB)	Wake Forest
Alzheimer’s Disease	Shankle Neurology Clinic
Parkinson’s Disease	Shankle Neurology Clinic
Parkinson’s Disease	University of Massachusetts
Multi-System Atrophy	University of Massachusetts
Cognition in Diabetics	Harvard Medical School
Cognition in multiple sclerosis (MS)	Johns Hopkins
Traumatic Brain Injury	Department of Defense
PTSD	Department of Defense
PTSD	Mount Sinai School of Medicine
Neuropathic Pain	Johns Hopkins
Mood and Anxiety Disorders	Karolinska University (Sweden)
Life Extension	Leiden University (Netherlands)
Autism	Pastorus

Sign Up Now to Invest With Kurve!

*Founders, board, and management own 51% of common shares

16825 48th West Suite 434
Lynnwood, WA 98037

info@kurvetx.com
(425) 640-9249

Transfer Agent: KoreConX Inc. | Broker-Dealer: Rialto Markets LLC | Escrow Agent: Wilmington Trust NA The Refund Policy: There are no refunds or cancelations of commitments once the subscription agreement is signed and submitted. Please contact compliace@rialtomarkets.com with questions regarding a cancelation or refund.

Rialto Markets LLC is the Onboarding Agent for this offering and is not an affiliate of nor connected with the Issuer.

Rialto Markets LLC is NOT placing or selling these securities on behalf of the Issuer.

Rialto Markets LLC is NOT soliciting this investment nor making any recommendations by collecting, reviewing, and processing your application for investment.

Rialto Markets LLC conducts Anti-Money Laundering, Identity, and Bad Actor Disqualification reviews of the Issuer, and ensures they are a registered business in good standing.

Rialto Markets LLC is NOT validating or approving the information provided by the Issuer or the Issuer itself.

Contact information below is provided for applicants to make inquiries and requests of Rialto Markets LLC regarding the general application process, the status of the application, or general Reg A regulation-related information. Rialto Markets LLC may direct applicants to specific sections of the Offering Statement to locate information or answers to their inquiry but does not opine or provide guidance on Issuer-related matters.

The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment. The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

This investment involves a high degree of risk. This investment is suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investment. Furthermore, investors must understand that such investment is illiquid and is expected to continue to be illiquid for an indefinite period of time. No public market exists for the securities.

This information is presented only for the purpose of providing a general overview of clinical trials. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.